物质信息
ID:449300
名称和标识
IUPAC标准名
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-1H-purin-6-one
别名
AcycloguanosineZoviraxSupraviranMirolexZyclirVirovirAcyclovirHerpetadSoothelipAciclovirAviraxGeavirMilavirActivirCycloviranVirasorb
IUPAC传统名
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-1H-purin-6-one
数据登录号
CAS号
化合物性质
药理学性质
生物活性机理
and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase.
Aciclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA.
Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts aciclovir to the aciclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase,
Guanosine analog that acts as an antimetabolite.
Once incorporated, aciclovir triphosphate inhibits DNA synthesis by acting as a chain terminator.
产品相关信息
应用领域
Used especially against herpes.
Antiviral agent.
描述信息
暂无数据
点击上传数据
分子图谱
暂无数据
点击上传数据
参考文献
• Jennings, R. et al., Antimicrob. Agents Chemother., 1999, 43, 53-61, (acyclovir elaidate)
• Plass, M. et al., J.C.S. Perkin 2, 1999, 2641-2646, (uv, pmr, ir, Raman)
• Ger. Pat., 1976, 2 539 963; CA, 84, 180300p, (synth)
• Birnbaum, G.I. et al., Can. J. Chem., 1984, 62, 2646, (cryst struct)
• Alhede, B. et al., J.O.C., 1991, 56, 2139, (synth, cmr)
• Buck, I.M. et al., Tetrahedron, 1994, 50, 9195-9206, (synth)
• Stimac, A. et al., Synthesis, 1990, 461-464, (synth)
• Gao, H. et al., Synth. Commun., 2001, 31, 1399-1419, (synth)
• Arndt, K.A. et al., J. Am. Acad. Dermatol., 1988, 18, 188, (adverse effects)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 602; 628
• Ormrod, D. et al., Drugs, 2000, 59, 839-863; 1317-1359
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AEC700; AEC725
• Elion, G.B. et al., Proc. Natl. Acad. Sci. U.S.A., 1977, 74, 5716, (pharmacol)
• Krasny, H.C. et al., Biochem. Pharmacol., 1986, 35, 4339, (metab)
• U.K. Pat., 1993, Norsk Hydro A/S, 2 260 319; CA, 119, 271633g, (acyclovir elaidate)
• Rees, P.J. et al., J. Antimicrob. Chemother., 1986, 18, 215-222, (pharmacokinet)
• Gao, H. et al., Synthesis, 2000, 329-351, (rev)
• Eur. Pat., 1984, Wellcome, 108 285; CA, 101, 192401e, (Desciclovir, synth, pharmacol)
• Krenitsky, T.A. et al., Proc. Natl. Acad. Sci. U.S.A., 1984, 81, 3209-3213, (synth, pharmacol)
• Chu, C.K. et al., J. Het. Chem., 1986, 23, 289, (rev)
• Petty, B.G. et al., Antimicrob. Agents Chemother., 1987, 31, 1317-1322, (pharmacokinet)
• Fiddian, A.P., Appl. Virol., 1984, 103, (rev, pharmacol)
• Reardon, J.E. et al., Adv. Pharmacol., 1991, 22, 1, (rev)
• Wagstaff, A.J. et al., Drugs, 1994, 47, 153, (rev)
• Kelley, J.L. et al., J. Het. Chem., 1986, 23, 271, (synth)
• Radl, S. et al., Cesk. Farm., 1987, 36, 58, (synth)
• Matsumoto, H. et al., Chem. Pharm. Bull., 1988, 36, 1153, (synth)
• De Miranda, P. et al., Antiviral Chem. Chemother., 1992, 3, 1, (metab, rev)